There is an urgent and unmet need to develop therapeutics for TB with shorter treatment durations and with efficacy against MDR-TB. The Liverpool-based investigators have a strong track record in anti-infective drug discovery and development, and have in the past 5 years established a mini-portfolio of preclinical discovery projects for TB that have progressed to Lead identification. The Bloomsbury SET award will support completion of pre-clinical data packs and IP filing, towards progression of one or more series to candidate declaration . The investigators’ ongoing activities and existing partnerships in drug discovery and extensive collaborative networks will bring to bear significant added value to this project.